Endogenous nitric oxide causes vasodilation in rat bone marrow, bone, and spleen during accelerated hematopoiesis
- PMID: 7957715
Endogenous nitric oxide causes vasodilation in rat bone marrow, bone, and spleen during accelerated hematopoiesis
Abstract
There is a marked increase in blood flow to rat bone marrow during increased erythro- or granulopoiesis. Furthermore, stimulated erythropoiesis increases bone and splenic perfusion, whereas granulopoietic hyperactivity does not. The mechanism behind this hyperemia is unknown. Endogenous nitric oxide (NO) has been shown to be a potent vasodilator in many vascular beds, but its possible role in the regulation of bone marrow, bone, and spleen vascular resistance and perfusion has not been explored. With the radioactive microsphere method, we determined blood flow to bone marrow, bone, and spleen in awake rats. Eight rats were bled heavily (1.5% of body weight), eight others received 10 micrograms/kg recombinant human granulocyte colony-stimulating factor (rhG-CSF) subcutaneously, and eight other untreated rats served as controls. We used 300 micrograms/kg, intraaortal, of the potent NO synthase blocker N-monomethyl-L-arginine (L-NMMA) (Calbiochem, La Jolla, CA). The inhibition of NO formation was subsequently reversed with 1000 mg/kg intraaortal arginine. Marrow vascular resistance was reduced to approximately 30% of control baseline in the experimental rats 10 hours after hematopoietic stimulation with either bleeding or rhG-CSF. Concomitantly, marrow blood flow increased to about 260% of control baseline in the bled rats, while it almost tripled after rhG-CSF injection. Inhibition of NO formation increased marrow vascular resistance in all three groups. After L-NMMA treatment, marrow perfusion was reduced to about 50% of baseline in the bled and 75% in the rhG-CSF-treated rats, while perfusion in the controls remained apparently unaltered. These changes were completely reversed with arginine. The increases in vascular resistance after NO blockade could not be explained by a concomitant change in arterial blood pressure. L-NMMA increased the vascular resistance in the bone and spleen both in controls and in stimulated rats, but since arterial blood pressure rose proportionally, perfusion remained unchanged. We conclude that NO plays an important role in the regulation of both the normal bone marrow vascular tone and the vasodilation that occurs during accelerated hematopoiesis. NO apparently also regulates bone and splenic vascular tone, but less conspicuously than in the stimulated bone marrow.
Similar articles
-
The leukopoietic cytokine granulocyte colony-stimulating factor increases blood flow to rat bone marrow.Exp Hematol. 1993 Feb;21(2):231-5. Exp Hematol. 1993. PMID: 7678810
-
Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine.Cancer Res. 1997 Mar 1;57(5):948-55. Cancer Res. 1997. PMID: 9041200
-
Nitric oxide as a mediator of parasympathetic vasodilation in ocular and extraocular tissues in the rabbit.Invest Ophthalmol Vis Sci. 1996 Sep;37(10):2110-9. Invest Ophthalmol Vis Sci. 1996. PMID: 8814150
-
Blood flow to the haemopoietic bone marrow.Acta Physiol Scand. 1997 Apr;159(4):269-76. doi: 10.1046/j.1365-201X.1997.00107.x. Acta Physiol Scand. 1997. PMID: 9146747 Review.
-
Role of spleen in integrated control of splanchnic vascular tone: physiology and pathophysiology.Can J Physiol Pharmacol. 2009 Jan;87(1):1-7. doi: 10.1139/Y08-103. Can J Physiol Pharmacol. 2009. PMID: 19142210 Review.
Cited by
-
Nitric oxide-mediated vasodilation in human bone.Microcirculation. 2024 Feb;31(2):e12842. doi: 10.1111/micc.12842. Epub 2023 Dec 22. Microcirculation. 2024. PMID: 38133925 Free PMC article.
-
Vascular deficits contributing to skeletal fragility in type 1 diabetes.Front Clin Diabetes Healthc. 2023 Oct 6;4:1272804. doi: 10.3389/fcdhc.2023.1272804. eCollection 2023. Front Clin Diabetes Healthc. 2023. PMID: 37867730 Free PMC article. Review.